コンテンツへスキップ
MediciNova, Inc.
  Message from CEO
  Our Mission
  Company Profile
  Management Team
  History
  Ongoing Clinical Studies
    About MN-166 (Ibudilast)
    ALS
    Oncology / Glioblastoma
    DCM
    CIPN
    ARDS / Lung Injury
    About MN-001(Tipelukast)
    NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  Press Release
  Event
  Media Archive
  Annual Report
  SEC filing
  Stock Quote -TSE
  Stock Quote -Nasdaq
  Historical Price Lookup
  Investment Calculator
  Analyst Coverage
  Corporate Governance
  Information Request
  Corporate Presentation & Resarch Reports
    Progressive Multiple Sclerosis (Progressive MS)
    Amyotrophic Lateral Sclerosis (ALS)
    Oncology / Glioblastoma
    Substance Dependence and Addiction
    MN-166 (ibudilast) News Articles
    MN-166 (ibudilast) Publications
  MN-001 Presentation
  Contact Us
Japanese site
  • About Us
    • Message from CEO
    • Our Mission
    • Company Profile
    • Management Team
    • History
  • Clinical Development
    • Ongoing Clinical Trial
    • MN-166 (Ibudilast)
      • About MN-166 (Ibudilast)
      • ALS
      • Oncology / Glioblastoma
      • DCM
      • CIPN
      • ARDS / Lung Injury
    • MN-001 ( tipelukast)
      • About MN-001(Tipelukast)
      • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  • Investor Relations
    • Press Release
    • Event
    • Media Archive
    • Annual Report
    • SEC filing
    • Stock Quote -TSE
    • Stock Quote -Nasdaq
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
    • Corporate Governance
    • Information Request
  • Presentation
    • Corporate Presentation and Equity Research Analyst Reports
    • MN-166 Presentation
      • Progressive Multiple Sclerosis (Progressive MS)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Oncology / Glioblastoma
      • Substance Dependence and Addiction
      • MN-166 (ibudilast) News Articles
      • MN-166 (ibudilast) Publications
    • MN-001 Presentation
  • Contact Us

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MN-166
2024.06.052024.08.20
Page Top
medicinova_en
MediciNova, Inc.

関連記事

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

MN-166

MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology

MN-166

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder

MN-166

MN-166のALS治療適応に対するFDAのオーファンドラッグ指定のお知らせ

MN-001

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

MN-166

ALS(筋萎縮性側索硬化症)を適応とするMN-166のフェーズ3臨床試験に関するFDAからのポジティブなフィードバック受領のお知らせ

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy
    • About Us
      • Message from CEO
      • Our Mission
      • Company Profile
      • Management Team
      • History
    • Clinical Development
      • Ongoing Clinical Trial
      • MN-166 (Ibudilast)
        • About MN-166 (Ibudilast)
        • ALS
        • Oncology / Glioblastoma
        • DCM
        • CIPN
        • ARDS / Lung Injury
      • MN-001 ( tipelukast)
        • About MN-001(Tipelukast)
        • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
    • Investor Relations
      • Press Release
      • Event
      • Media Archive
      • Annual Report
      • SEC filing
      • Stock Quote -TSE
      • Stock Quote -Nasdaq
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
      • Corporate Governance
      • Information Request
    • Presentation
      • Corporate Presentation and Equity Research Analyst Reports
      • MN-166 Presentation
        • Progressive Multiple Sclerosis (Progressive MS)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Oncology / Glioblastoma
        • Substance Dependence and Addiction
        • MN-166 (ibudilast) News Articles
        • MN-166 (ibudilast) Publications
      • MN-001 Presentation
    • Contact Us
  • MediciNova, Inc.